IRB #

IRB00007391

Title

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to compare the efficacy and safety of eribulin with dacarbazine in patients with advanced leiomyosarcoma or liposarcoma who have received at least two prior therapies.

Medical Condition(s)

Soft Tissue

Eligibility Criteria

*Subjects should have either liposarcoma or leiomyosarcoma which is incurable by surgery or radiation therapy.
*Subjects should be 18 years or older at the time of consent.
*Subjects must have received at least 2 prior treatment regiments, one of which must have included an anythracycline.
*Subject's must not have had any other cancer (except for non-melanoma skin cancer or carcinoma in-situ within the past 5 years.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Approximately 4 years.

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

Eisai, Inc.

Recruitment End

Compensation Provided

No